UEG WEEK 2024

The new kids on the block

The battle of IL-23s

TL1A - a hot new target?

S1P modulators - dead or alive?

What is early disease? Getting the right drug to the…

P19 antagonists - on the way to disease clearence!?

Hot topic deescalation - patients' wish & scientific…

S1P modulators - efficacy, safety and the future…

Prime time for ultrasound use

Fatigue - still a black box?

RW data of Ustekinumab and the role of biosimilars

JAKies side effects - what is the current place for…

Long term persistence of Ustekinumab in moderate to…

Tamuzimod for long term extension

Impact of Guselkumab maintenance on histological and…

Mirikizumab is able to induce disease clearance in UC

Guselkumab in UC - QUASAR maintenance data

anti-TL1A in UC

Παρατεταμένη ανταπόκριση στο ustekinumab ασθενών με…

Guselkumab bei Colitis ulcerosa - die QUASAR…

Tamuzimod per estensione a lungo termine

Effects of Mirikizumab & Ustekinumab on histological…

Real world data on Risankizumab effectiveness in CD

Risankizumab efficacy in CD

Guselkumab in patients with Crohn´s disease

Ryzankizumab w chorobie Crohna – oczekiwania vs.…

Dati real-world di efficacia di Risankizumab in…

Efficacité du risankizumab dans la maladie de Crohn

Evidence based surgery for IBD?

Dose adjustment for subcutaneous Infliximab

How to diagnose PSC associated to IBD

Comment diagnostiquer la CSP associée aux MiCi?

Dosisanpassung bei subkutanem Infliximab

כירורגיה מבוססת ראיות במחלות מעי דלקתיות?

Live biotherapeutic product for acute pouchitis

Extended induction response in week 12 in non-responder…

Long-term extension of Mirikizumab - barely any…

What treatment after Vedolizumab in UC?

Extended induction treatment in active UC can capture…

Long-term Extension von Mirikizumab - kaum noch…

Long-term Extension von Mirikizumab - deutlicher…

Levend biotherapeutisch medicijn voor acute pouchitis

Quel traitement après le Vedolizumab dans la RCH?

Induzione prolungata con Mirikizumab in pazienti che…

Vedolizumab is more effective in early Crohn´s disease

Early disease loves Vedolizumab

Vedolizumab in early CD

Data on interaction between biologics and…

Ileocecal resection in CD – GI functional consequences

Interactions entre le traitements biologiques et la…

Zaburzenia czynności przewodu pokarmowego po resekcji…

Früher Einsatz von Vedolizumab bei Patienten mit Morbus…

De efficaciteit van vedolizumab is beter bij vroege…

Tulisokibart - new anti-TL1A agent for treating CD

Tulisokibart - a new therapeutic option in UC

RXC008 - novel mechanism of action for fibrostenosing…

Cellular therapies in IBD – Old and New

Divine support for intestinal fibrosis in UC & CD

טיפולים תאיים במחלות מעי דלקתיות-ישן וחדש

Dezidierte Unterstützung bei intestinaler Fibrose bei…

Topische JAKies - auf ein Neues!

RXC008 - un nuovo meccanismo d’azione per la malattia…

Tulisokibart - eine neue Therapieoption bei CU

Mirikizumab improves fatigue in patients with CD

Colorectal cancer risk and biologicals in IBD patients

Long term safety of ozanimod in UC

Risico op colorectaal carcinoom bij IBD patienten onder…

VERDICT - Update on week 32 data

Positive effect of biologics on bowel urgency

IBS overlapping IBD

Το Upadacitinib αποκαθιστά την ποιότητα της ζωής…

VERDICT Update: Daten nach Woche 32

Biologika haben positiven Effekt auf den Stuhldrang

Impact of diet on risk of disease flare in CD

Focus on nutrition